30086-17-0

Basic information

• Product Name: 4-FLUORO-1H-IMIDAZOLE
• Synonyms: 4-FLUORO-1H-IMIDAZOLE;4-Fluoro-1(3)H-imidazole;1H-Imidazole, 5-fluoro-;5-Fluoro-1H-imidazole;4-Fluoroimidazole;Nsc 208718;4-FI;4(5)-Fluoroimidazole
• CAS NO: 30086-17-0
• Molecular Formula: C₃H₃FN₂
• Molecular Weight: 86.0677232
• Product Categories: Heterocyclic Compounds;Heterocycles;Fluorinated heterocyclic series
• Mol File: 30086-17-0.mol

Chemical Properties

• Melting Point: 101-1040C
• Boiling Point: 261 °C at 760 mmHg
• Flash Point: 111.7 °C
• Appearance: /
• Density: 1.32 g/cm³
• Vapor Pressure: 0.0192mmHg at 25°C
• Refractive Index: 1.487
• Storage Temp.: Refrigerator
• Solubility: DMSO, Methanol
• PKA: 12.42±0.10(Predicted)
• CAS DataBase Reference: 4-FLUORO-1H-IMIDAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-FLUORO-1H-IMIDAZOLE(30086-17-0)
• EPA Substance Registry System: 4-FLUORO-1H-IMIDAZOLE(30086-17-0)

Safety Data

• Hazardous Substances Data: 30086-17-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-Fluoro-1H-imidazole is used as an antiviral agent for its ability to inhibit the biosynthesis of polynucleotides, which are essential for the replication and transcription of viral genetic material. This property makes it a potential candidate for the development of antiviral drugs that can target a wide range of viruses and help in the treatment of viral infections.
Additionally, due to its chemical properties as an off-white solid, 4-Fluoro-1H-imidazole can be formulated into various pharmaceutical dosage forms, such as tablets, capsules, or suspensions, to ensure optimal bioavailability and therapeutic efficacy.

InChI:InChI=1/C3H3FN2/c4-3-1-5-2-6-3/h1-2H,(H,5,6)

Upstream product

• 3034-38-6 1H-4⁽⁵⁾-nitroimidazole 
• 78162-58-0 N,N-dimethyl-1H-imidazole-1-sulfonamide 
• 4919-03-3 4-amino-1H-imidazole 

Downstream Products

• 1248592-26-8 methyl {2-[(4-fluoro-1H-imidazol-1-yl)methyl]phenyl}acetate 

Relevant articles and documents

Determination of inter-ionic and intra-ionic interactions in a monofluorinated imidazolium ionic liquid by a combination of X-ray crystallography and NOE NMR spectroscopy

We report the very first application of a Transient 1D 1H{19F} NOE NMR experiment in neat ionic liquids. In comparison with classical 2D HOESY NMR spectroscopy, a substantial reduction in measurement time is gained with comparable quality and information content of the spectra. In combination with classical X-ray crystallography, we have applied this technique for the determination of inter-ionic distances (i.e. probabilities of presence) utilizing an ionic liquid containing a monofluorinated imidazolium cation. Copyright

Synthesis of 4,5-difluoroimidazole

5-Fluoroimidazole-4-carboxylic acid ethyl ester was converted to the corresponding hydrazide. Oxidation of the hydrazide to the carbonyl azide and Curtius rearrangement in t-butyl alcohol produced 4-t-butyloxycarbonylamino-5-fluoroimidazole. Dissolution o

Novel imidazobenzazepine derivatives as dual H1/5-HT 2A antagonists for the treatment of sleep disorders

A novel imidazobenzazepine template (5a) with potent dual H 1/5-HT2A antagonist activity was identified. Application of a zwitterionic approach to this poorly selective and poorly developable starting point successfully delivered a class of high quality leads, 3-[4-(3-R1-2-R-5H-imidazo[1,2-b][2]benzazepin-11-yl)-1-piperazinyl]- 2,2-dimethylpropanoic acids (e.g., 9, 19, 20, and 21), characterized by potent and balanced H1/5-HT2A receptor antagonist activities and good developability profiles.

NOVEL COMPOUNDS

Disclosed are N-{[(1R,4S,6R)-3-(2-pyridinylcarbonyl)-3-azabicyclo[4.1.0]hept-4-yl]methyl}-2-heteroarylamine derivatives and their use as pharmaceuticals.

IMIDAZOBENZAZEPINE COMPOUNDS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM (CNS) DISEASES

This invention relates to novel novel imidazobenzazepine derivatives of formula (I) or a pharmaceutically acceptable salt thereof, for treating diseases and conditions of the central nervous system (CNS), in particular sleep disorders.

Regio- and stereoselective glycosylation: Synthesis of 5-haloimidazole α-ribonucleosides

We describe the synthesis of novel 5-haloimidazole ribonucleosides as precursors of modified cobalamins. A regio- and stereoselective glycosylation of protected ribose with silylated 4(5)-haloimidazoles produces 5-haloimidazole ribonucleosides predominant